Alkeon Capital Management LLC Acquires 100,000 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Alkeon Capital Management LLC grew its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 2.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 3,904,096 shares of the company’s stock after purchasing an additional 100,000 shares during the period. Alkeon Capital Management LLC owned approximately 0.06% of ORIC Pharmaceuticals worth $40,017,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the business. Price T Rowe Associates Inc. MD grew its position in shares of ORIC Pharmaceuticals by 140.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock valued at $21,543,000 after buying an additional 915,175 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of ORIC Pharmaceuticals by 27.9% in the first quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company’s stock worth $39,628,000 after acquiring an additional 629,536 shares during the period. Millennium Management LLC boosted its holdings in ORIC Pharmaceuticals by 297.4% in the second quarter. Millennium Management LLC now owns 782,299 shares of the company’s stock valued at $5,531,000 after acquiring an additional 585,447 shares during the last quarter. First Turn Management LLC increased its position in ORIC Pharmaceuticals by 38.1% during the 2nd quarter. First Turn Management LLC now owns 1,515,960 shares of the company’s stock valued at $10,718,000 after purchasing an additional 418,389 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in ORIC Pharmaceuticals by 190.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 466,662 shares of the company’s stock worth $3,299,000 after purchasing an additional 305,860 shares during the last quarter. Institutional investors and hedge funds own 95.05% of the company’s stock.

ORIC Pharmaceuticals Stock Up 1.7 %

Shares of ORIC Pharmaceuticals stock opened at $9.97 on Friday. The business has a 50-day simple moving average of $9.57 and a 200 day simple moving average of $9.33. ORIC Pharmaceuticals, Inc. has a one year low of $6.33 and a one year high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.01). Research analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ORIC. Stifel Nicolaus assumed coverage on shares of ORIC Pharmaceuticals in a research note on Friday, September 6th. They issued a “buy” rating and a $20.00 price objective on the stock. Wells Fargo & Company initiated coverage on shares of ORIC Pharmaceuticals in a research report on Thursday, October 31st. They set an “overweight” rating and a $20.00 price target on the stock. Oppenheimer lowered their price objective on ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of ORIC Pharmaceuticals in a research report on Monday, November 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a report on Monday, September 23rd. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, ORIC Pharmaceuticals has a consensus rating of “Buy” and an average target price of $18.29.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.